|
Providing products and services to treat
and monitor diseases is at the core of Taj Pharmaceutical's
activities in all major therapeutic areas. We are
concentrating our efforts especially on those areas, where
there are important medical needs and where patients can
benefit from an adequate treatment regimen. Our product
range makes it possible to offer real improvements to
doctors, hospitals and patients.
Focusing on prescription drugs, we currently engage in the
following areas (amongst others):
For many of these areas and the corresponding indications,
Taj Pharmaceuticals has provided a large range of
therapeutic options. Please view a selection of major
prescription drugs by accessing the current
Selected Products
overview.
| |
TAJ PHARMACEUTICALS
GROUP ANNUAL REPORT |
|
| |
Annual
Report 2011
(PDF, 5295Kb) |
 |
 |
|
|
The above report is a comprehensive report on a
company's activities throughout the preceding year. The
report is intended to give shareholders and other
interested people information about the company's
activities and financial performance. |
|
| |
|
| |
|
| |
ANNUAL SUSTAINABILITY
REPORT - TAJ PHARMACEUTICALS
GROUP |
|
| |
|
Annual Sustainability
Report 2011 (PDF,
1607Kb) |
|
 |
|
|
The above
sustainability report is an organizational
report that will provide information about
economic, environmental, social and governance
performance. |
|
|
| |
|
| |
|
| |
TAJ PHARMACEUTICALS
GROUP FIGURE AND REPORTS |
| |
Financial Report for FY 2011
(IFRS, audited)
 (PDF,
1416Kb) |
| |
Financial Report for FY 2010 (IFRS,
audited)
(PDF, 868Kb) |
| |
Financial Report for FY 2009 (IFRS,
audited)
(PDF,
1243Kb) |
| |
Financial Report for FY 2008 (IFRS,
audited)
(PDF,
1376Kb) |
| |
Financial Report for FY 2007 (IFRS,
audited)
(PDF,
1128Kb) |
| |
Financial Report for FY 2006 (IFRS,
audited)
(PDF,
791Kb) |
| |
Financial Report for FY 2005 (IFRS,
audited)
(PDF,
761Kb) |
| |
Financial Report for FY 2004 (IFRS,
audited)
(PDF,
727Kb) |
| |
|
| |
|
Note: Taj Pharmaceuticals Limited (the "Company")
believes that the information included in the Investor
Relations section of this website was correct at the
time it was added to the website. However, the Company
expressly disclaims any duty to update the information
on the website and makes no representation or warranty
as to accuracy and completeness of the contents of this
Investors Relations section of the website or any other
section of the website. Access to and use of the
information on this website is at the user's own risk.
The Company assumes no responsibility for any errors or
omissions in the content of this website and disclaims
any liability for damages of any kind (whether direct,
consequential or punitive) arising out of the use of
this website or the information contained on the website
or on links to or from this website.
The Investor Relations section of this website contains
forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934. All
statements other than statements of historical facts,
included on this website regarding the Company's
strategy, expected future financial position, results of
operations, cash flows, financing plans, discovery and
development of products, strategic alliances,
competitive position, plans and objectives of management
are forward-looking statements. Words such as
"anticipate," "believe," "estimate," "expect," "intend,"
"plan," "will" and other similar expressions help
identify forward-looking statements, although not all
forward-looking statements contain these identifying
words. In particular, any statements regarding the
Company's financial results and outlook, the continued
implementation of the Company's strategic plan, the
development of the Company's pipeline, the commencement
of Phase 3 clinical trials for Puricase (pegloticase)
are forward-looking statements. These forward-looking
statements involve substantial risks and uncertainties
and are based on current expectations, assumptions,
estimates and projections about the Company's business
and the biopharmaceutical and specialty pharmaceutical
industries in which the Company operates. Such risks and
uncertainties include, but are not limited to, the delay
or failure in developing Puricase (pegloticase) and
other product candidates; difficulties of expanding the
Company's product portfolio through in-licensing or
acquisition; not being able to manufacture commercial
quantities of our products; not gaining market
acceptance sufficient to justify development and
commercialization costs if our products are approved for
marketing; introduction of generic competition for API;
fluctuations in buying patterns of wholesalers;
potential future returns of API or other products; the
Company continuing to incur substantial net losses for
the foreseeable future; difficulties in obtaining
financing; potential development of alternative
technologies or more effective products by competitors;
reliance on third-parties to manufacture, market and
distribute many of the Company's products; risks of
maintaining protection for the Company's intellectual
property; risks of an adverse determination in any
future intellectual property litigation; and risks
associated with stringent government regulation of the
biopharmaceutical and specialty pharmaceutical
industries and other factors set forth more fully in
certain reports filed with the Securities and Exchange
Commission, to which investors are referred for further
information. The Company may not actually achieve the
plans, intentions or expectations disclosed in its
forward-looking statements, and you should not place
undue reliance on the Company's forward-looking
statements. Actual results or events could differ
materially from the plans, intentions and expectations
disclosed in the forward-looking statements that the
Company makes. The Company's forward-looking statements
do not reflect the potential impact of any future
acquisitions, mergers, dispositions, joint ventures or
investments that the Company may make. The Company does
not have a policy of updating or revising
forward-looking statements and assumes no obligation to
update any forward-looking statements.
|
Quality
